Volatile organic compound

Chrysler Halcyon Concept Pushes Innovative Boundaries, Offers Forward-looking Vision of Brand's All-electric Future

Retrieved on: 
Tuesday, February 13, 2024

"The Chrysler Halcyon Concept creates a level of serenity that fully represents the Halcyon name.

Key Points: 
  • "The Chrysler Halcyon Concept creates a level of serenity that fully represents the Halcyon name.
  • The Chrysler Halcyon Concept is the latest in a steady progression of futuristic concepts representing the brand's electrification transformation.
  • Previously, the brand revealed the Chrysler Portal Concept in 2017, the Chrysler Airflow Concept in 2022 and the Chrysler Synthesis Cockpit Demonstrator in 2023.
  • The Chrysler Halcyon Concept, designed on the STLA Large platform, offers an aerodynamic, streamlined and uncompromising vision of the Chrysler brand's future exterior character.

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

Retrieved on: 
Tuesday, February 13, 2024

ZUG, Switzerland and BOSTON, Feb. 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced today that the European Commission has granted conditional marketing authorization to CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene edited therapy. CASGEVY is approved for the treatment of patients who are 12 years of age and older with severe sickle cell disease (SCD) characterized by recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT), for whom hematopoietic stem cell (HSC) transplantation is appropriate and a human leukocyte antigen matched related HSC donor is not available.

Key Points: 
  • “The approval by the European Commission is yet another important regulatory milestone underscoring the potentially transformative benefit of CASGEVY for patients with severe sickle cell disease and transfusion-dependent beta thalassemia,” said Samarth Kulkarni, Chairman and Chief Executive Officer of CRISPR Therapeutics.
  • Vertex is working closely with national health authorities in the European Union (EU) to secure access for eligible patients as quickly as possible.
  • Through this work, they have secured early access for eligible TDT patients in France ahead of the national reimbursement process.
  • There are currently three activated ATCs in the EU with plans to activate a total of approximately 25 centers across Europe.

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Retrieved on: 
Tuesday, February 13, 2024

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Commission has granted conditional marketing authorization to CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Commission has granted conditional marketing authorization to CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy.
  • CASGEVY is the only genetic therapy approved for SCD and TDT patients in the European Union (EU) and with this approval, there are now more than 8,000 patients potentially eligible for treatment.
  • Through this work, Vertex has secured early access for eligible TDT patients in France ahead of the national reimbursement process.
  • Vertex continues to engage with hospitals experienced in stem cell transplantation to establish a network of independently operated authorized treatment centers (ATCs) for the administration of CASGEVY.

New to The Street Signs General Enterprise Ventures, Inc. To 6-Part Media Series

Retrieved on: 
Monday, February 12, 2024

NEW YORK, Feb. 12, 2024 (GLOBE NEWSWIRE) -- FMW Media Corp.'s New to The Street announces signing a six-month media contract with General Enterprise Ventures, Inc. (OTCPink: GEVI) ($GEVI).

Key Points: 
  • NEW YORK, Feb. 12, 2024 (GLOBE NEWSWIRE) -- FMW Media Corp.'s New to The Street announces signing a six-month media contract with General Enterprise Ventures, Inc. (OTCPink: GEVI) ($GEVI).
  • New to The Street's TV anchors will talk with General Enterprises Venture, Inc.'s Management about the Company.
  • The Show's producers will create and design each General Enterprise Venture's televised series to keep viewers informed and updated accordingly, bringing attention to business fundamentals and ongoing successes.
  • Throughout the series, General Enterprise Ventures will share Management's corporate vision with viewers, highlighting critical operational successes and future advancements in IP holdings.

Your unique smell can provide clues about how healthy you are

Retrieved on: 
Friday, February 9, 2024

They give clues about who we are, and how healthy we are.

Key Points: 
  • They give clues about who we are, and how healthy we are.
  • Since ancient Greek times, we’ve known that we smell differently when we are unwell.
  • While we rely on blood analysis today, ancient Greek physicians used smell to diagnose maladies.
  • This discovery has led to research programmes involving Joy Milner to identify the precise smell of this disease.

Where do VOCs come from?

  • Sweating produces extra nutrients for these bacteria to metabolise which can result in particularly odorous VOCs.
  • Odour from sweat only makes up a fraction of the scents from VOCs though.
  • Scientists think skin VOCs can offer insights into how the microbiome’s bacteria and the human body work together to maintain our health and protect us from disease.
  • We use mass spectrometry to see this as the average human nose is not sophisticated enough to detect these VOCs.

What has science shown about love pheromones?

  • Mice for example have microbes which contribute to a particularly smelly compound called trimethylamine, which allows mice to verify the species of a potential mate.
  • Scientists have yet to fully decode skin – or other VOCs that are released from our bodies.
  • But evidence for human love pheromones so far is controversial at best.


Aoife Morrin receives funding from Science Foundation Ireland.

'Premium Clean' expands its environmentally friendly business

Retrieved on: 
Friday, February 9, 2024

The increasing demand for specialised eco-friendly cleaning services meant the company quickly expanded its operations to cater to the needs of the growing clientele.

Key Points: 
  • The increasing demand for specialised eco-friendly cleaning services meant the company quickly expanded its operations to cater to the needs of the growing clientele.
  • Frequently, business owners and facility managers express a desire to transition towards more environmentally friendly cleaning practices, but they often question the efficiency of green products when compared to traditional ones due to lack of information.
  • Traditional cleaning products often release volatile organic compounds (VOCs), contributing to poor air quality.
  • In contrast, many eco-friendly cleaning products are produced using sustainable manufacturing techniques that rely on renewable energy sources.

EWG redefines mattress safety standards, launches EWG VERIFIED®: Mattresses with Naturepedic

Retrieved on: 
Wednesday, February 7, 2024

These Naturepedic mattresses proudly bear the EWG VERIFIED ® mark , setting a new benchmark for mattress makers.

Key Points: 
  • These Naturepedic mattresses proudly bear the EWG VERIFIED ® mark , setting a new benchmark for mattress makers.
  • "This is an important milestone for EWG, Naturepedic and the mattress industry," said EWG President Ken Cook .
  • "Naturepedic is proud to debut the world's first EWG VERIFIED mattress," said Naturepedic founder and technical director, Barry Cik .
  • In the absence of modern safety standards for mattresses, EWG VERIFIED: Mattresses fills a crucial gap, providing consumers with trusted, healthier options.

Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge

Retrieved on: 
Monday, February 5, 2024

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the publication of preclinical non-human primate data demonstrating the potential of its COVID-19 vaccine to protect against multiple SARS-CoV-2 variants of concern (VOC)s. The data, which were previously presented at the International Congress of Mucosal Immunology 2022, are reported in the current issue of Vaccines.

Key Points: 
  • “The data published in Vaccines support the potential of our vaccine platform to stimulate potent mucosal cross-reactive IgA responses to multiple VOCs and reduce viral transmission.
  • All three vaccines induced neutralizing antibodies in both the peripheral and mucosal compartments, which was enhanced with a boost immunization.
  • Viral replication and infectious particle shedding were significantly reduced in immunized animals after challenge with beta variant SARS-CoV-2.
  • Vaxart believes these data support the potential for its vaccines to enhance mucosal responses and reduce community transmission, in addition to preventing severe disease.

Global Indoor Air Quality (IAQ) Equipment Market Report 2023-2029: New Ground-Breaking Air Purification Technologies for Enhancing IAQ - ResearchAndMarkets.com

Retrieved on: 
Monday, January 29, 2024

The "Global Indoor Air Quality (IAQ) Equipment Market - Product Types and End-Use Applications" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Indoor Air Quality (IAQ) Equipment Market - Product Types and End-Use Applications" report has been added to ResearchAndMarkets.com's offering.
  • Several parameters are used for measuring Indoor Air Quality (IAQ), the most important of which comprise levels of carbon dioxide (CO2), relative humidity, volatile organic compounds (VOCs), particulate matter (PM2.5 & PM10) and bioaerosols.
  • While it is imperative that these be maintained within limits as prescribed by regulatory authorities, in most cases, achieving the same is next to impossible.
  • The aforementioned approaches comprise the use of a vast variety of IAQ equipment available today, including Air Filters, Air Purifiers, Carbon Monoxide (CO) Detectors, Dehumidifiers, Humidifiers, Ultraviolet (UV) Lamps and Ventilation Systems, to name a few.

Austin-based Air Purifier Company Reports Strong 2023 Growth: Alen Announces 33 Percent Growth in 2023 Sales and Expanded Footprint in Lowe’s Stores Nationwide

Retrieved on: 
Thursday, January 18, 2024

As a testament to its dedication to cleaner, healthier indoor environments, Alen solidified its position as a dominant player in the market.

Key Points: 
  • As a testament to its dedication to cleaner, healthier indoor environments, Alen solidified its position as a dominant player in the market.
  • Alen.com witnessed strong demand for its products and an impressive revenue growth of 27% in 2023.
  • National Reach: Alen's units sold in all 50 states through Alen.com and the expanded partnership with Lowes that put Alen into over 1,700 stores nationwide.
  • Protecting Schools: Alen significantly impacted education in 2023, supplying air purifiers to over 135 schools nationwide.